← all works
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet Oncology
- Topic
- Cancer Immunotherapy and Biomarkers
- Field
- Medicine
- Canadian institutions
- William Osler Health System
- Funders
- F. Hoffmann-La Roche
- Keywords
- CarboplatinMedicinePaclitaxelAtezolizumabChemotherapyOncologyNab-paclitaxelOpen labelInternal medicineLung cancerCisplatinCancerRandomized controlled trialNivolumabImmunotherapy
- Has abstract in OpenAlex
- no